Moreover, treatment with empagliflozin augmented the expression of SMAD7, possibly leading to the downregulation of TGF-β1, one of the key mediators of inflammation and fibrosis in diabetic nephropathy. This evidence concerns the gene SMAD7 and diabetic kidney disease.